Letter: early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply

Tsz Hong Yiu; Yanna Ko; Aviv Pudipeddi; Patrizia Natale; Rupert W. Leong

doi:10.1111/apt.18057

Letter: early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply

Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong

Research output: Contribution to journal › Article › peer-review

Abstract

We appreciate the insightful commentary on our paper by Alahmad et al. They effectively underscored the dynamic landscape of advanced therapies in inflammatory bowel disease (IBD) by addressing the efficacy of a new advanced therapy—risankizumab—aligning with the focus of our systematic review. We agree on the need to increase the coverage of persistence research to cover newer drugs for IBD. However, it is important to note that this is not yet possible due to the current paucity of publications of persistence data from real-world cohorts on these new drugs.

Original language	English
Pages (from-to)	103-104
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	60
Issue number	1
DOIs	https://doi.org/10.1111/apt.18057
Publication status	Published - Jul 2024

Access to Document

10.1111/apt.18057

Cite this

@article{0fffea7c4b9b43dc9e559020156cd048,

title = "Letter: early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply",

abstract = "We appreciate the insightful commentary on our paper by Alahmad et al. They effectively underscored the dynamic landscape of advanced therapies in inflammatory bowel disease (IBD) by addressing the efficacy of a new advanced therapy—risankizumab—aligning with the focus of our systematic review. We agree on the need to increase the coverage of persistence research to cover newer drugs for IBD. However, it is important to note that this is not yet possible due to the current paucity of publications of persistence data from real-world cohorts on these new drugs.",

author = "Yiu, {Tsz Hong} and Yanna Ko and Aviv Pudipeddi and Patrizia Natale and Leong, {Rupert W.}",

year = "2024",

month = jul,

doi = "10.1111/apt.18057",

language = "English",

volume = "60",

pages = "103--104",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc",

number = "1",

}

Letter: early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply. / Yiu, Tsz Hong; Ko, Yanna; Pudipeddi, Aviv et al.
In: Alimentary Pharmacology and Therapeutics, Vol. 60, No. 1, 07.2024, p. 103-104.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Letter

T2 - early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply

AU - Yiu, Tsz Hong

AU - Ko, Yanna

AU - Pudipeddi, Aviv

AU - Natale, Patrizia

AU - Leong, Rupert W.

PY - 2024/7

Y1 - 2024/7

N2 - We appreciate the insightful commentary on our paper by Alahmad et al. They effectively underscored the dynamic landscape of advanced therapies in inflammatory bowel disease (IBD) by addressing the efficacy of a new advanced therapy—risankizumab—aligning with the focus of our systematic review. We agree on the need to increase the coverage of persistence research to cover newer drugs for IBD. However, it is important to note that this is not yet possible due to the current paucity of publications of persistence data from real-world cohorts on these new drugs.

AB - We appreciate the insightful commentary on our paper by Alahmad et al. They effectively underscored the dynamic landscape of advanced therapies in inflammatory bowel disease (IBD) by addressing the efficacy of a new advanced therapy—risankizumab—aligning with the focus of our systematic review. We agree on the need to increase the coverage of persistence research to cover newer drugs for IBD. However, it is important to note that this is not yet possible due to the current paucity of publications of persistence data from real-world cohorts on these new drugs.

UR - http://www.scopus.com/inward/record.url?scp=85193981866&partnerID=8YFLogxK

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1111/apt.18057

U2 - 10.1111/apt.18057

DO - 10.1111/apt.18057

M3 - Article

C2 - 38779926

AN - SCOPUS:85193981866

SN - 0269-2813

VL - 60

SP - 103

EP - 104

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 1

ER -

Letter: early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease: Authors' reply

Abstract

Access to Document

Other files and links

Fingerprint

Cite this